4D Molecular Therapeutics Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) Transcript
Great. Good afternoon, everyone. Thanks for sticking with us for the last session of the day for our inaugural virtual genetic medicines day. Just a reminder, my name is Dae Gon Ha, one of the biotech analysts here at Stifel. (Conference Instructions)
But for now, the next 30 minutes, we're going to be discussing 4D Molecular. And from the company, we're going to be having both the CEO David Kirn; as well as a Chief Operating Officer and President, Fred Kamal.
So, David, I'll turn it over to you. David's got a couple of slides as an introductory remarks and then we'll dive into Q&A. So, David, thank you.
All right. Thanks for having us. Welcome, everyone. We'll just introduce the company through a few key slides upfront. So we're 4D Molecular Therapeutics, FDMT. This is our pipeline. We have a number of sustainable, large market gene therapy product opportunities in our portfolio.
We have products in ophthalmology, lung,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
